I don't agree with belly up comment because PACB has positive profit if you exclude R&D. R&D cost is high since it's still a new company.
I do agree though that PACB might be acquired buy bigger player...
These are probably granted through some predefined terms...If they buy with their $ then it's a bullish sign, not when it's granted.
If you believe (I do) that next decade will dominate the personalized medicine then it's one of the best stock to won.
100%. They have the highest, longest most accurite reads out there. It will continue to gain new customers, and as prices come down and reads go even higher, I easily see this over taking Illumina as time progresses. I'm really awaiting the new diagnostic equipment unveiling. If it's what's been rumored, then off we go big time.
Sentiment: Strong Buy
Roche already invested 75M in Pacbio and exclusive right for diagnostic instrument. And Pacbio already passed phase 2, plan to release it in early 2016 as planned. We have to wait and see.
Nanopore might be good for small gene/segment detection but it has not demonstrated if they can assemble large organism.
This can't be a standalone company like ILMN. It has to go belly up or be taken over by another company with money. Helicos is the fate here.
I am surprised that this board is so quiet? IMO PACB seems to be on the verge of a breakout?
With $17mm+ in revs and big time partnerships, why is this board nonexistent?
Pointless bashing is not needed here.
The latest ONT published spec: 3000 pores for Minion II, 100K readlength, cost $20 for the first hour of data (5G). The Promethion has about 140K pores (many many Minions bound together). This is close to RS, which has 150K active dots. The accuracy is rumored to be above 90%.
If ONT delivers, it is a PacBio killer. Ilumina is less affected due to its focus on high precision, short reads and ultra high throughput.
Last time I checked, days to cover short are 20. High upward pressure. Insiders are buying, best technology, progress as planned, Big Roche backing up...
Don't care if price goes down. Buying opportunity for me. But maybe not many opportunities remaining for shortsellers?
Sentiment: Strong Buy
I bet that was why they didn't mention the booking number in the CC, and quite lamely use some bogus confidentiality excuse to hide the number. Stock price will test recent low of 5 dollars.
Which Genomic company did really shine so far? Millenium did not have a product until they bought Velcade rights...developed by another company. Tell me how do you design a drug based on a single mutation or multiple mutations. Answer me if you care. I bet, you are not familiar with science. Yes, sequencing can detect somatic mutations in certain tissue DNAs but then what?
There you have it, ladies and gentleman. Genomics is a bust. Just another friendly hint from madmonsoon2000.
Personalized medicine is a total BS. Most of the genomic DNA is just junk. If you find a mutation in the introns, that may not give you any clue, let alone a personalized medicine. Moreover, most the diseases are multi-factoral or environmental. Personalized medicine would not be much help. It is rather a sexy word for grant money.
Of course it should work. But that is not the question. Can it survive the ruthless competition from the Goliath? It will see meet a slow death. Mark my word!